{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023412","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.914523+00:00","generated_at":"2026-06-11T10:39:33.243833+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Q2 revenue $8.5M, net loss $5.1M; arimoclomol NDA resubmission on track for Q4 2023","bullets":["Net revenue $8.5M in Q2 2023 vs $1.3M YoY, driven by $5M AZSTARYS milestone and royalties.","Net loss $5.1M ($0.15/share) vs $24.0M ($0.70) in Q2 2022; prior year included $17.7M acquired IPR&D charge.","Cash $87.4M as of June 30, 2023, supporting operations into 2026; $5M milestone received after quarter-end.","Pre-submission meeting with FDA for arimoclomol NDA completed; resubmission expected Q4 2023.","Phase 2 KP1077 IH trial enrolling; interim data expected Q3 2023; topline data H1 2024; narcolepsy IND opened."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023412","json":"https://secwatch.observer/filing/0001437749-23-023412.json","markdown":"https://secwatch.observer/filing/0001437749-23-023412.md","text":"https://secwatch.observer/filing/0001437749-23-023412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923023412/0001437749-23-023412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923023412/zvra20230519_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:39:33.243833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f8c081802480e5ac0abb60d4ce1d1554f3fb77a","claim":"ZEVRA THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: revenue $8.5 million, net income ($5.1) million, EPS ($0.15).","evidence_excerpt":"Net revenue for Q2 2023 was $8.5 million compared to Q2 2022 net revenue of $1.3 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923023412/0001437749-23-023412-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$8.5 million"},{"label":"Net income","value":"($5.1) million"},{"label":"EPS","value":"($0.15)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}